drugset / Trial / NCT01340651
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).
Timeline
- Start
- 2011-03
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 25 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 50 mg | Oral |